CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) [Yahoo! Finance]
BNP PARIBAS SPONS ADR (BNPQY)
NASDAQ:AMEX Investor Relations:
invest.bnpparibas.com/en
Company Research
Source: Yahoo! Finance
CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , the specialty pharmaceutical company that develops products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology. CROSSJECT is in the advanced stages of developing and registering ZEPIZURE®, an injectable for the treatment of epileptic seizures, and announces the initiation of coverage of its stock by Portzamparc (BNP Paribas Group). Coverage of CROSSJECT shares has been initiated with a study entitled “The needles will soon be nothing more than a bad memory” which includes a “Strong Buy” recommendation with a target price of €4.50 CROSSJECT shares are now covered by: - Alpha Value - Invest Securities - Maxim Group - Oddo - Portzamparc (BNP Paribas Group) CROSSJECT SA (Euronext : ALCJ ; www.CROSSJECT.com) is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. CROSSJ
Show less
Read more
Impact Snapshot
Event Time:
BNPQY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNPQY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNPQY alerts
High impacting BNP PARIBAS SPONS ADR news events
Weekly update
A roundup of the hottest topics
BNPQY
News
- BNP Paribas: Shares Close In On Tangible Book Value, But Remain Attractive [Seeking Alpha]Seeking Alpha
- France Buy Now Pay Later Business and Investment Report 2026: A $27.42 Billion Market by 2031, Growing at a CAGR of 12.6% - Bank-Led Credit Portfolios and White-Label Models Dominate Competition [Yahoo! Finance]Yahoo! Finance
- BNP Paribas (OTCMKTS:BNPQY) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- BNP Paribas (OTCMKTS:BNPQY) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- Best Value Stocks to Buy for January 21st [Yahoo! Finance]Yahoo! Finance